Work

Discovery and Development of VX-950, a Novel, Covalent, and Reversible Inhibitor of Hepatitis C Virus NS3.4A Serine Protease

Year: 2006

Type: article

Source: Infectious Disorders - Drug Targets

DOI: 10.2174/187152606776056706

Authors: C. Lin, A. Kwong, R. Perni

Institution: Vertex Pharmaceuticals (United States)

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W2108836992

FWCI: 7.48

Cites:

Cited by: 243

Related to: 10